Education
About Us
Working with TipRanks
Follow Us
Impedimed Limited (AU:IPD)
ASX:IPD
IPD Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.11
Previous CloseN/A
Volume149.09K
Average Volume (3M)841.06K
Market Cap
$80.02M
Enterprise ValueAU$122.17M
Total Cash (Recent Filing)AU$9.65M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.40
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding2,025,728,400
10 Day Avg. Volume790,161
30 Day Avg. Volume841,060
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)24.15
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.17Price Target Upside315.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Impedimed Limited News
PremiumCompany Announcements
ImpediMed Unaffected by New U.S. Tariffs
PremiumCompany Announcements
Impedimed Limited Announces Cessation of Securities
PremiumCompany Announcements
ImpediMed Limited Reports Revenue Growth Despite Continued Losses
PremiumCompany Announcements
ImpediMed Secures $15M Growth Capital to Drive Expansion
PremiumCompany Announcements
Impedimed Director Increases Stake Through Fee ConversionPremiumCompany Announcements
Impedimed Limited Announces Director’s Shares Acquisition
PremiumCompany Announcements
ImpediMed Limited Reports Director’s Share Acquisition---
Options Prices
Currently, No data available
---
Ownership Overview
0.50% Insiders
<0.01%
Mutual Funds
<0.01% Other Institutional Investors
99.49% Public Companies and
Individual Investors
IPD FAQ
What was Impedimed Limited’s price range in the past 12 months?
Impedimed Limited lowest share price was AU$0.04 and its highest was AU$0.10 in the past 12 months.
What is Impedimed Limited’s market cap?
Impedimed Limited’s market cap is $80.02M.
When is Impedimed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Impedimed Limited’s earnings last quarter?
Impedimed Limited released its earnings results on Feb 26, 2024. The company reported -AU$0.005 earnings per share for the quarter, the consensus estimate of -AU$0.005 by AU$0.
Is Impedimed Limited overvalued?
According to Wall Street analysts Impedimed Limited’s price is currently Undervalued.
Does Impedimed Limited pay dividends?
Impedimed Limited does not currently pay dividends.
What is Impedimed Limited’s EPS estimate?
Impedimed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Impedimed Limited have?
Impedimed Limited has 2,025,728,400 shares outstanding.
What happened to Impedimed Limited’s price movement after its last earnings report?
Impedimed Limited reported an EPS of -AU$0.005 in its last earnings report, expectations of -AU$0.005. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of Impedimed Limited?
Currently, no hedge funds are holding shares in AU:IPD
---
Impedimed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.17 (315.97% Upside)
AU$0.17 (315.97% Upside)
Blogger Sentiment
Bullish
AU:IPD Sentiment 85%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $22.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.55%
12-Months-Change
Fundamentals
Return on Equity
-51.08%
Trailing 12-Months
Asset Growth
-39.31%
Trailing 12-Months
Company Description
Impedimed Limited
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
---
IPD Stock 12 Month Forecast
Average Price Target
AU$0.17
▲(315.97% Upside)
Technical Analysis
Cochlear Limited
―
CSL
―
Nanosonics Limited
―
Ramelius Resources Limited
―
Resonance Health Ltd
―
Best Analysts Covering IPD
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+20.88%
reiterated a buy rating last month
Copying Scott Power's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +20.88% per trade.
---